#United States #Annapolis #Atopic Dermatitis #Zabalafin Hydrogel #Alphyn Biologics

Alphyn Biologics Fundraises $25 Million for Clinical Advancements

In a significant move to upscale its operations, Alphyn Biologics, Inc., a pioneer in clinical dermatology, has announced the successful closure of its Series B financing, raising an impressive $25 million. This funding round was notably oversubscribed, indicating strong interest from the investment community, and will be chiefly directed towards advancing the company’s dermatology pipeline, particularly focusing on atopic dermatitis (AD) and the molluscum contagiosum virus (MCV).

Expansion of Clinical Trials

Alphyn’s recent financing will primarily support the Phase 2b global clinical trial for its lead therapeutic candidate, Zabalafin Hydrogel, aimed at treating atopic dermatitis. This innovative treatment is designed to address the multi-faceted nature of AD by simultaneously tackling inflammation, itch, bacterial presence, and dryness—components that often coexist and exacerbate this prevalent skin condition.

Alongside the clinical trial for AD, Alphyn will initiate a second Phase 2 clinical program for tackling the molluscum contagiosum virus, which primarily affects children and manifests as an irritating and contagious skin infection. The funding will also enable the company to boost its supply of raw materials essential for drug production.

Investor Support and Company Vision

QCA Investment Group led this financing round, joined by existing investors such as Angel Physicians Fund and Serial Stage Venture Partners, alongside new stakeholders drawn by Alphyn’s potential. Alphyn’s CEO, Neal Koller, expressed immense gratitude for the robust support received from investors, emphasizing that their backing showcases confidence in the company's unique Multi-Target Therapeutics® approach.

"This financing reflects their confidence in our Multi-Target Therapeutic Drug Platform and our unique and highly differentiated drug candidates for atopic dermatitis and the molluscum contagiosum virus," Koller stated, highlighting that the company is positioned well to embark on key milestones, including pivotal Phase 3 trials.

Zabalafin Hydrogel’s Unique Approach

One of the standout characteristics of Zabalafin Hydrogel is its ability to effectively address the interconnected challenges posed by both AD and MCV. Unlike existing treatments that often focus on singular aspects of the diseases, Zabalafin Hydrogel is designed to provide a holistic treatment approach, targeting not just the symptoms like itch and inflammation, but also the underlying issues such as virus presence and bacterial infections.

The innovative formulation promises not only efficacy but also tolerability for patients, which is crucial for treatment adherence and long-term management. According to industry experts, its success could pave the way for a revolutionary change in how these skin conditions are approached therapeutically, presenting a new frontier in dermatological care.

Tony Shipley, chairman of QCA Investment Group, praised Alphyn’s groundbreaking approach, noting that the combination of effective natural ingredients could lead to a paradigm shift in the treatment landscape for these common yet challenging dermatological issues. Shipley remarked, "With an experienced leadership team and concentrated execution strategies, Alphyn is poised to meet tremendous market needs and provide patients with innovative therapies."

The Future of Alphyn Biologics

With a firm operational foundation established in 2020 and approximately $34 million raised to date, Alphyn Biologics is rapidly emerging as a key player in the dermatological landscape. Headquartered in Annapolis, Maryland, with operations in Cincinnati, Ohio, and subsidiaries in Australia and Austria, the company is on track to enhance its portfolio of transformative topical treatments.

"Our commitment to developing first-in-class Multi-Target Therapeutics® reflects our dedication to patients suffering from significant skin diseases," Koller noted. As the company gears up for its clinical trials, many in the dermatology field are keenly observing its progress, anticipating potential breakthroughs that could significantly enhance patient outcomes in skin care.

As developments continue, the dermatology community awaits with optimism the results from these clinical trials, hopeful for new solutions that go beyond conventional treatments and genuinely alleviate the plight of millions affected by these skin conditions.